Funder
U.S. Department of Defense
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. TCGA Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
2. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–78.
3. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60(8):2155–62.
4. Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de The H. TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008;75(2):132–9.
5. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Borresen-Dale AL, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13):3569–80.